Verve Therapeutics anticipates initial data from the Heart-2 Phase 1b trial of VERVE-102, targeting PCSK9, in Q2 2025, including safety and efficacy data.
Recent advances in AI, deep learning, and multi-omics technologies have enabled researchers to identify key pathways for anti-aging drug development, with promising results emerging from early clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.